Navigation Links
Share Issue Gives Cellectricon SEK 89 Million to Continue its Rapid Market Expansion
Date:2/21/2008

GOTHENBURG, Sweden, February 21 /PRNewswire/ -- With two successful international product launches, Swedish biotech firm Cellectricon is entering a new expansion phase. The share issue will strengthen Cellectricon's financial capacity prior to a number of significant product launches in 2008-2009. These products have been developed in close collaboration with leading global pharmaceutical companies to meet the industry's increasing demand for fully automated, highly efficient systems for pre-clinical pharmaceutical development.

"Cellectricon is now entering a new expansion phase, in which the company will soon launch two large-scale systems that will revolutionize drug discovery. This capital will enable us to continue our rapid expansion in the United States, Europe, and Asia," said Dr. Mattias Karlsson, Cellectricon's CEO.

In 2008 Cellectricon will launch the first of their large-scale screening system, Cellaxess(R)HT, which has been developed in close cooperation with one of the world's largest pharmaceutical companies. Cellaxess(R)HT will be the only system on the market that enables large-scale supply of genetic material for cells and is tailor made for high throughput RNAi screening.

About Cellectricon

Cellectricon AB is a Swedish biotech company that is a successful provider of groundbreaking products to the pharmaceutical industry that increase efficiency in pre-clinical pharmaceutical development. Cellectricon has already successfully launched two products onto the market that have been sold to ten of the 12 largest pharmaceutical companies in the world. In 2007 the company increased its revenue by almost 50%. In 2008-2009 launch the high-performance systems Cellaxess(R)HT for RNAi screening and Dynaflow(R)HT for ion channel screening. Cellectricon's forthcoming products address a market that is estimated to be US $1.4 billion by 2010.


'/>"/>
SOURCE Cellectricon AB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
2. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
3. CardioDynamics Provides 2007 Shareholder Meeting Update
4. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
5. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
6. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
7. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
8. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
9. Neuralstem Shares Accepted for Trading on Amex(R)
10. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
11. STALLERGENES : Strong Business Growth: +17% and Earnings Per Share up 30%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... -- S&P Capital IQ (MHFI) announced today that it ... Therapeutics Holdings Inc . MabVax Therapeutics ... focused on the development of vaccine and antibody-based therapies ... cancer. MabVax has discovered a pipeline of human monoclonal ... by patients who have been immunized against targeted cancers. ...
(Date:2/26/2015)... Mass., Feb. 26, 2015   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... provided 2015 goals, other key objectives, and financial ... call today at 4:30 p.m. EST to review ... update.  To participate in today,s call by telephone, ...
(Date:2/26/2015)... The Movement for Indefinite Life Extension ... extension technologies and awareness. The event is taking place ... March 21st 2015, in a live Google Hangout broadcast ... Founder of MILE, says, “Our lives are in our ... for Indefinite Life Extension is raising awareness about bio-sciences ...
(Date:2/26/2015)... Feb. 26, 2015 BioEnterprise today announced that ... attracted more than $2 billion in growth funding during ... national investors, strategic sources, state – including the Ohio ... the $2 billion has been raised in the past ... the heels of the BioEnterprise Midwest Healthcare Growth ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4
... Inc. (Nasdaq: IDEV ) announced today the ... entitled "Once Daily Dosage Forms,of Trospium," which is ... Supernus Pharmaceuticals, Inc., The ,978 patent covers ... of trospium chloride which is indicated for the,treatment ...
... BRUNSWICK, N.J., Aug. 13 At the upcoming ... R&D Team,Leader, will present "Silicone Elastomer Gels: New ... place in Philadelphia, September 16-17., According to ... molecular,structures that provide differentiated performance features for wound ...
... - Test Cleared to Screen Donated Blood for Hepatitis ... C, on Fully and Semi-Automated Instrument Systems -, ... ) announced today that the US Food and Drug ... the,PROCLEIX(R) ULTRIO(R) assay to screen donated blood for the ...
Cached Biology Technology:Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM) 2Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM) 3Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference 2FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 2FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 3FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 4
(Date:1/22/2015)... 13, 2015 Technology Showcase, Hall E -   EyeLock ... today announced it will showcase its EyeLock ID technology integrated ... Department of Energy,s Oak Ridge National Laboratory (ORNL) ... EyeLock,s iris identity authentication technology is being used to validate ...
(Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
(Date:1/22/2015)... and POINT ROBERTS, Washington , January 20, ... leading sectors including technology and tech stocks, releases video from ... master pickpocket and security consultant Apollo Robbins . ... talks about the Wocket™ biometric smart wallet, a product of ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... drugs is a huge industry with an annual turnover of ... extremely serious. Half of the malaria medication sold there could ... UK have now developed a technique that could resolve the ... have a prototype ready. It will resemble a small briefcase, ...
... Mass. Expanding their scope of study on the ... (WPI) have reported the surprise finding from a small ... of Staphylococcus aureus ( S. aureus ) ... was reported in a poster presentation at the American ...
... Global degradation of ecosystems is widely believed to threaten ... it is on average improving globally, both in poor ... in the September issue of BioScience dissects ... paradox is "critical to guiding future management of ecosystem ...
Cached Biology News:Problem of fake medicines in developing countries could be solved 2Cranberry juice shows promise blocking Staph infections 2Researchers analyze 'the environmentalist's paradox' 2
...
... is a completely redesigned and updated version ... accepts the full line of well-proven Alpha ... in thermal performance as the DNA Engine ... easy transport of protocols among platforms. ...
... marker mix was designed specifically to aid the ... a complement of seven reduced and denatured proteins ... who use markers to assess 2-D system performance ... proteins undergoing 2-D separation and analysis. , ...
... The DNA Engine Tetrad thermal ... beyond the pioneering PTC-200 DNA Engine ... times the capacity with a footprint ... high throughput for laboratories that run ...
Biology Products: